Work

Early Pseudoprogression After Tarlatamab in Small‐Cell Lung Cancer: A Case Report

Year: 2025

Type: article

Abstract: Pseudoprogression, a transient radiographic flare caused by immune infiltration, is common after immune-checkpoint inhibitors but has not been reported with tarlatamab, a bispecific T-cell engager approved for third-line small-cell lung cancer (SCLC). A 57-year-old woman with extensive-stage SCLC and syndrome of inappropriate antidiuretic hormone secretion (SIADH) received tarlatamab. Within hours, she developed bone pain; Day 7 imaging showed marked tumour swelling and pleural effusion despite negative cytology and rising serum sodium. Therapy continued. By Day 13, computed tomography demonstrated regression of thoracic and hepatic lesions and falling pro-gastrin-releasing peptide (pro-GRP). Early pseudoprogression and paraneoplastic biomarker improvement may predict efficacy.

Source: Respirology Case Reports

DOI: 10.1002/rcr2.70319

Authors: Yoshio Nakano, Hiroka Serizawa, Yuri Enomoto, Yusuke Kuze, Norio Okamoto, Iwao Gohma

Institution: Sakai Municipal Hospital

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,130